当前位置: 首页 >> 检索结果
161. Building community capacity in mental health care with the Strong Minds-Strong Communities programme: a randomised controlled trial in the USA.
作者: Margarita Alegría.;Gabriela Livas Stein.;Mario Cruz-Gonzalez.;Irene Falgas-Bague.;Sheri Lapatin Markle.;Kari M Eddington.;Andrew Supple.;Larimar Fuentes.;Claire Poindexter.;Patrick E Shrout.
来源: Lancet. 2025年406卷10505期832-845页
Provider shortages and lack of culturally responsive care limit mental health services in reaching multicultural populations worldwide. We examined the effectiveness of a psychoeducational intervention aimed at building community capacity to address depression and anxiety among racial, ethnic, and linguistic minoritised adults.
162. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Rohit Loomba.;Erin Morgan.;Keyvan Yousefi.;Dan Li.;Richard Geary.;Sanjay Bhanot.;Naim Alkhouri.; .
来源: Lancet. 2025年406卷10505期821-831页
ION224, a liver-directed antisense inhibitor of diacylglycerol O-acyltransferase 2 (DGAT2), suppresses de novo lipogenesis, an important metabolic pathway associated with lipotoxicity and the underlying inflammation, hepatocellular injury, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This study aimed to prospectively assess the safety and efficacy of ION224 in patients with MASH and fibrosis.
171. INTERLACE: not a new standard for cervical cancer chemoradiation.
作者: Primoz Petric.;Jacob Christian Lindegaard.;Maximillian Paul Schmid.;Ina Jürgenliemk-Schulz.;Umesh Mahantshetty.;Christian Kirisits.;Richard Pötter.
来源: Lancet. 2025年406卷10505期806-807页 178. Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials.
作者: Lonnie Pyne.;Patrick Rossignol.;Cameron Giles.;Mats Junek.;Patrick B Mark.;Martin Gallagher.;Janak R de Zoysa.;P J Devereaux.;Michael Walsh.
来源: Lancet. 2025年406卷10505期811-820页
Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but their effects in patients with kidney failure requiring dialysis are uncertain. We aimed to assess the efficacy and safety of mineralocorticoid receptor antagonists in this patient population.
|